Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 67, Number 10, November 28, 2006
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siddall, P. J.
Right arrow Articles by Murphy, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siddall, P. J.
Right arrow Articles by Murphy, T. K.
Related Collections
Right arrow All Clinical trials
Right arrow Clinical trials Methodology/study design
Right arrow All Pain
Right arrow Central pain
Right arrow Spinal cord trauma
Right arrowRelated Article
NEUROLOGY 2006;67:1792-1800
© 2006 American Academy of Neurology

Pregabalin in central neuropathic pain associated with spinal cord injury

A placebo-controlled trial P. J. Siddall, MBBS, PhD, M. J. Cousins, MD, DSc, A. Otte, MD, PhD, T. Griesing, PhD, R. Chambers, MSPH and T. K. Murphy, PhD

From the Pain Management Research Institute (P.J.S., M.J.C.), University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia; International Medical Research (A.O.), Pfizer Global Pharmaceuticals, Freiburg, Germany; and Pfizer Pharmaceuticals Group (T.G., R.C., T.K.M.), New York, NY.

Address correspondence and reprint requests to Dr. Philip J. Siddall, Pain Management and Research Institute, University of Sydney, Royal North Shore Hospital, Sydney, NSW, 2065, Australia; e-mail: phils{at}med.usyd.edu.au

Objective: To evaluate pregabalin in central neuropathic pain associated with spinal cord injury.

Methods: A 12-week, multicenter study of patients randomized to either flexible-dose pregabalin 150 to 600 mg/day (n = 70) or placebo (n = 67), administered BID. Patients were allowed to remain on existing, stable pain therapy. The primary efficacy variable was the endpoint mean pain score, derived from patients’ last 7 days daily pain diary entries. Key secondary endpoints included pain responder rates, the SF-MPQ, sleep interference, mood, and the patient global measure of change.

Results: The mean baseline pain score was 6.54 in the pregabalin group and 6.73 in the placebo group. The mean endpoint pain score was lower in the pregabalin group (4.62) than the placebo group (6.27; p < 0.001), with efficacy observed as early as week 1 and maintained for the duration of the study. The average pregabalin dose after the 3-week stabilization phase was 460 mg/day. Pregabalin was significantly superior to placebo in endpoint assessments on the SF-MPQ. The ≥30% and ≥50% pain responder rates were higher with pregabalin than placebo (p < 0.05). Pregabalin was associated with improvements in disturbed sleep (p < 0.001) and anxiety (p < 0.05), and more patients reported global improvement at endpoint in the pregabalin group (p < 0.001). Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events.

Conclusions: Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury.

Supported by Pfizer Global Pharmaceuticals, New York, NY.

Disclosures: Drs. Otte, Griesing, Chambers, and Murphy are employees of Pfizer. Dr. Siddall and Prof. Cousins have received an honorarium for a presentation at a Pfizer-sponsored symposium at an international meeting.

Received October 24, 2005. Accepted in final form August 14, 2006.


Related Article

November 28 Highlights
Neurology 2006 67: 1736-1737. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
D. M. Simpson, G. Schifitto, D. B. Clifford, T. K. Murphy, E. Durso-De Cruz, P. Glue, E. Whalen, B. Emir, G. N. Scott, R. Freeman, et al.
Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial
Neurology, February 2, 2010; 74(5): 413 - 420.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
T. L Smith, A. Baldwin, L. L Cunningham Jr, and A. M Cook
Rash Associated with Pregabalin Use
Ann. Pharmacother., December 1, 2008; 42(12): 1899 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. L. Abrahm, M. B. Banffy, and M. B. Harris
Spinal Cord Compression in Patients With Advanced Metastatic Cancer: "All I Care About Is Walking and Living My Life"
JAMA, February 27, 2008; 299(8): 937 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
N. M. Gajraj
Pregabalin: Its Pharmacology and Use in Pain Management
Anesth. Analg., December 1, 2007; 105(6): 1805 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. C. Que, P. J. Siddall, and M. J. Cousins
Pain Management in a Patient With Intractable Spinal Cord Injury Pain: A Case Report and Literature Review
Anesth. Analg., November 1, 2007; 105(5): 1462 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. P. Kruszewski, J. A. Shane, P .J. Siddall, M . Cousins, A . Otte, T . Griesing, R . Chambers, and K . Murphy
PREGABALIN IN CENTRAL NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY: A PLACEBO-CONTROLLED TRIAL
Neurology, June 12, 2007; 68(24): 2158 - 2160.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Pregabalin in central neuropathic pain associated with spinal cord injury:A placebo-controlled trial
Stefan P. Kruszewski, MD, et al.
Neurology Online, 10 Mar 2007 [Full text]
Reply from the Authors
Philip J Siddall, et al.
Neurology Online, 10 Mar 2007 [Full text]